TLDR Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
The study analyzed 855 severe alopecia areata (AA) patients from two phase III trials, BRAVE-AA1 and BRAVE-AA2, who were treated with either 4mg or 2mg of baricitinib. Patients were categorized into early, gradual, and late responders based on when they first achieved ≥ 30% improvement from baseline in Severity of Alopecia Tool (SALT) score. Among patients treated with 4mg baricitinib, 33% were early responders, 28% were gradual, and 8% were late. For those treated with 2mg, the proportions were 20%, 23%, and 9% respectively. Early responders had a shorter trajectory to maximal clinical outcomes. Responders were more frequent in patients with short (< 4 years) episodes of hair loss. The study concluded that these subgroups are influenced by baseline characteristics and will help inform treatment expectations for scalp hair regrowth.
102 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”
Restoring hair bulb immune privilege is crucial for managing alopecia areata.
Baricitinib, approved for alopeciaareata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.
Eli Lilly's drug baricitinib showed effectiveness in treating alopeciaareata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.
A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.
In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.
The post discusses using ImageJ software to objectively track hair regrowth progress. The user is treating Androgen alopecia with dutasteride and minoxidil.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
